Award
NIH Reporter #5R01CA229409-07
Optimizing prognostic and predictive algorithms using residual disease (RD) genomic biomarkers in HER2+ and TNBC
Recipient
University of North Carolina at Chapel Hill, Department of Internal Medicine
Award Amount
$590,870.00
Ceiling
$590,870.00
Awarded
May 19, 2026
Identifier
5R01CA229409-07
Research project funded by the National Cancer Institute to develop prognostic algorithms and understand tumor-immune interactions in residual disease of HER2+ and triple negative breast cancer patients, aiming to improve personalized treatment and outcomes.
Description
This project aims to comprehensively examine tumor and microenvironmental factors determining outcomes in patients with residual disease after neoadjuvant therapy in HER2-positive and triple negative nonmetastatic breast cancer. It integrates RNA sequencing and clinical features from multiple clinical trials to develop prognostic algorithms, identify patients with good prognosis, and examine tumor-immune interactions using spatial transcriptomics to improve personalized treatment strategies and reduce overtreatment.